No Data
Joincare Pharmaceutical Group Industry (600380.SH): has already applied the world's most advanced AI models such as Deepseek in the research and development of Innovative Drugs.
On March 14, Gelonghui reported that Joincare Pharmaceutical Group Industry (600380.SH) stated on the interactive investor platform that the company has always attached great importance to the application of AI technology in drug development and has already utilized the most advanced global AI models such as Deepseek in the research and development of Innovative Drugs. This includes key areas such as target discovery, compound screening, molecular design, pharmaceutical research, and clinical research, aiming to reduce development costs and comprehensively improve research efficiency through cutting-edge Technology.
Joincare Pharmaceutical Group Industry (600380.SH): has fully applied DeepSeek.
Gelonghui reported on March 10 that Joincare Pharmaceutical Group Industry (600380.SH) stated on the interactive platform that DeepSeek has been fully applied and suggestions regarding DeepSeek will be seriously considered. Regarding the company's market communication and information disclosure, the company has maintained a proactive and standardized attitude. In 2024, the company issued a total of 199 announcement documents, more than 96% of A-share listed companies, to ensure that investors can understand the company's dynamics in a timely and comprehensive manner. Moreover, the company has also achieved significant results in information disclosure and investor relations management, and has been awarded by the Shanghai Stock Exchange for four consecutive years.
Joincare Pharmaceutical Group Industry (600380.SH): has repurchased a total of 2.34% of shares.
On March 3, Glonghui reported that Joincare Pharmaceutical Group Industry (600380.SH) announced that by February 2025, the company had repurchased a total of 992,800 shares through centralized bidding, accounting for 0.05% of the total share capital (1,874,200,420 shares), with the highest purchase price at 11.05 yuan/share, the lowest at 10.81 yuan/share, and a total amount paid of 10.8583 million yuan (including fees). As of the end of February 2025, the company had cumulatively repurchased 43,843,462 shares, accounting for the total share capital (1,874,200,420 shares).
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Livzon Gets Nod to Trial Reflux Esophagitis Drug
Joincare Pharmaceutical Group Industry (600380.SH): Received the drug clinical trial approval notice.
On February 12, Gelonghui reported that Joincare Pharmaceutical Group Industry (600380.SH) announced that its holding subsidiary Livzon Pharmaceutical Group Inc. (hereinafter referred to as Livzon) received the "Drug Clinical Trial Approval Notice" (Notice No. 2025LP00349) approved and issued by the National Medical Products Administration, permitting the clinical trial of injectable JP-1366. JP-1366 is a novel potassium ion competitive acid blocker (P-CAB), which works by competitively binding to the potassium ion binding site of the H+/K+-ATPase in gastric parietal cells to inhibit gastric acid secretion. P-
Are Strong Financial Prospects The Force That Is Driving The Momentum In Joincare Pharmaceutical Group Industry Co.,Ltd.'s SHSE:600380) Stock?
